BioSpace News Archive

Xeris Biopharma Holdings, Inc. today announced a collaboration agreement with Merck, with an option to license Xeris’ suspension-based formulation technology, XeriJect™

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has filed an application for clearance to begin a Phase 1/2a clinical trial of ARO-C3, the company’s investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with various complement mediated diseases.

SAB Biotherapeutics today announced the completion of its business combination with Big Cypress Acquisition Corp.

Innovation Pharmaceuticals today announced the Company anticipates reporting topline results the week of November 8th from its Phase 2 clinical trial of Brilacidin for treatment of moderate-to-severe COVID-19 in hospitalized patients

Arch Therapeutics, Inc. today announced that it will be presenting at the 2021 Symposium on Advanced Wound Care (SAWC) Fall.

Small Pharma Inc. today announced that it has received European patent grant number EP 3 463 323 as acceptance for its European patent application No. 17 728640.8.

Targovax will at 14:00 CEST today host a live webcast presentation held by the company’s newly appointed CEO Erik Digman Wiklund .

Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), today announced that it will release its third quarter 2021 financial results after market close on Tuesday, November 9, 2021.

Rain Therapeutics Inc., (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics, today announced that it will host a virtual Research and Development (R&D) day on Tuesday, November 9, 2021 from 11:00 am to 2:00 pm Eastern Time.

X4 Pharmaceuticals, Inc. today announced that it will report its financial results for the third quarter ended September 30, 2021, and provide an update on recent business highlights, on November 4, 2021.